Format

Send to

Choose Destination
Arch Dis Child. 2018 Mar;103(3):285-291. doi: 10.1136/archdischild-2016-311377. Epub 2017 Sep 12.

Treatment and management of children with haemolytic uraemic syndrome.

Author information

1
Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.
2
National Renal Complement Therapeutic Centre, Newcastle upon Tyne, UK.
3
Department of Paediatric Nephrology, Great North Children's Hospital, Sir James Spence Institute, Royal Victoria Infirmary, Newcastle upon Tyne, UK.

Abstract

Haemolytic uraemic syndrome (HUS), comprising microangiopathic haemolytic anaemia, thrombocytopaenia and acute kidney injury, remains the leading cause of paediatric intrinsic acute kidney injury, with peak incidence in children aged under 5 years. HUS most commonly occurs following infection with Shiga toxin-producing Escherichia coli (STEC-HUS). Additionally, HUS can occur as a result of inherited or acquired dysregulation of the alternative complement cascade (atypical HUS or aHUS) and in the setting of invasive pneumococcal infection. The field of HUS has been transformed by the discovery of the central role of complement in aHUS and the dawn of therapeutic complement inhibition. Herein, we address these three major forms of HUS in children, review the latest evidence for their treatment and discuss the management of STEC infection from presentation with bloody diarrhoea, through to development of fulminant HUS.

KEYWORDS:

general paediatrics; haematology; nephrology

Conflict of interest statement

Competing interests: SJ is a member of the scientific advisory board for the Alexion global aHUS Registry.

Publication type

Publication type

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center